Type II Diabetes Mellitus Clinical Trial
Official title:
Inhibition of Absorption of Cytoxic Lipid Peroxidation Products and Abnormalities of Postprandial Endothelial Function by Spice Polyphenols Fed Together With High Fat Meat Patty in Men With Type 2 Diabetes Mellitus or Impaired Glucose Tolerance
Polyphenols belong to the largest group of secondary metabolites produced by plants, mainly,
in response to biotic or abiotic stresses such as infections, wounding, UV irradiation,
exposure to ozone, pollutants, and other hostile environmental conditions. It is thought
that the molecular basis for the protective action of polyphenols in plants is their
antioxidant and free radical scavenging properties. These numerous phenolic compounds are
major biologically active components of spices, aromas, essential oils, and traditional
medicines. In order to investigate the impact of spice polyphenols on postprandial
flow-mediated dilation, nitric oxide, glucose, insulin, triglycerieds, oxidized LDL, and
cytoxic lipid peroxidation products (MDA) levels in men with type 2 diabetes, the
investigators propose to achieve the following specific aims using a randomized crossover
study design:
1. To determine the effect of a ground beef patty meal with and without polyphenol-rich
spices on postprandial levels of plasma oxidized LDL, triglycerides, insulin, glucose,
and malondialdehyde (MDA).
2. To determine the effect of a ground beef patty meal with and without polyphenol-rich
spices on postprandial levels of nitric oxide and flow-mediated dilation.
3. To determine the effect of a ground beef patty meal with and without a spice blend on
MDA accumulation in urine.
This study will determine whether spice polyphenols exert a beneficial effect by inhibition
of the absorption of lipotoxin MDA in males with type 2 diabetes mellitus.Men with diabetes
mellitus type 2 have been selected for this study to enable assessment of markers of
vascular health including nitric oxide in plasma and flow-mediated dilation. These findings
may help to explain the potentially harmful effects of oxidizable fats found in foods and
the important benefit of dietary polyphenols in ameliorating this potentially harmful
effect.
10 male subjects with type 2 diabetes mellitus who will be recruited based on inclusion and exclusion criteria. The study will be carried out in accordance with the guidelines of the Human Subjects Protection Committee of the University of California, Los Angeles. All subjects will give written informed consent before the study begins. After the screening visit, each subject will come to the Center for Human Nutrition on two 1-day test phases separated by at least one week. At each of phases, subjects will consume, in a random order, two different test meals consisting of either: a) a ground dark meat beef patty seasoned with salt only, or b) a ground dark meat beef patty seasoned with a spice mixture and salt. The subjects will be asked to avoid eating high fat meat meals and all spice products for 3 days before the day of each of the two experimental phases ;
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01952535 -
A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral HMS5552 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01196728 -
Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes
|
Phase 1 | |
Terminated |
NCT00997152 -
Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients
|
Phase 2 | |
Completed |
NCT02592421 -
SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2
|
Phase 3 | |
Completed |
NCT05544214 -
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01969084 -
The Effect of Linagliptin on Mitochondrial and Endothelial Function
|
Phase 4 | |
Terminated |
NCT01644201 -
A Study Evaluating the Effects of a High Viscosity Non-starch Polysaccharide (PolyGlycopleX® - PGX®) on Glycemic Control, Cardiometabolic Risk Factors and Weight Loss in Overweight and Obese Type II Diabetics
|
Phase 3 | |
Completed |
NCT01020123 -
Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients
|
Phase 2 | |
Completed |
NCT00995787 -
Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea
|
Phase 1 | |
Completed |
NCT01505426 -
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes Patients
|
Phase 3 | |
Completed |
NCT01262586 -
Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.
|
Phase 3 | |
Completed |
NCT00561171 -
Phase IIa Study to Investigate the Efficacy and Safety of SPP635 in Diabetic and Hypertensive Patients With Albuminuria
|
Phase 2 | |
Active, not recruiting |
NCT03912363 -
Intrapartum Glycemic Control With Insulin Infusion Versus Rotating Fluids
|
N/A | |
Completed |
NCT01868646 -
Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type II Diabetes Mellitus
|
Phase 4 | |
Active, not recruiting |
NCT06386328 -
A Clinical Trial to Evaluate the Food Effect of CKD-378
|
Phase 1 | |
Terminated |
NCT02749435 -
A Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With Type 2 Diabetes Mellitus
|
N/A | |
Completed |
NCT00894868 -
Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure
|
Phase 4 | |
Recruiting |
NCT01165190 -
Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue in Humans
|
N/A | |
Completed |
NCT01255085 -
Yellow Pea Protein and Fibre and Short Term Food Intake
|
N/A | |
Completed |
NCT02156349 -
A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients.
|
N/A |